QUESTION 11 1.       Introducing adherence in facilitating...

QUESTION 11

1.       Introducing adherence in facilitating treatment goals is something that would be necessary in a patient who has previously displayed nonadherence patterns.

A.

True

B.

False

3.75 points  

QUESTION 12

1.       Of the components of patient-focused interventions to enhance adherence, which component includes the following strategies: adaptive thinking, use of cues, and support?

A.

Motivation

B.

Skills

C.

Logistics

D.

Education

3.75 points  

QUESTION 13

1.       G-protein coupled receptors are targets for several psychiatric medications. Given what we know about these receptors, what is the ultimate result we will see when one of them is activated in a way that would potentiate an action?

A.

Intracellular activation of second messengers

B.

Protein phosphorylation

C.

Modification of gene expression

3.75 points  

QUESTION 14

1.       Neurotransmitters are defined by four essential characteristics. These are:

A.

Neurotransmitters are synthesized within presynaptic neurons.

B.

Depolarization of a neuron results in the release of a neurotransmitter, which exerts a multitude of actions on the postsynaptic neuron.

C.

Their action on postsynaptic neurons can be replicated by administering a drug that mimics the activity of the endogenous neurotransmitter.

D.

Their action in the synaptic cleft is terminated by a specific action.

E.

A, C, and D only

3.75 points  

QUESTION 15

1.       G-protein coupled receptors are examples of what type of effector pathway?

A.

Slow effector pathways

B.

Rapid effector pathways

C.

NMDA glutamate receptor pathways

D.

Modulated effector pathways

3.75 points  

QUESTION 16

1.       The synaptic cleft is best characterized by which of the following statements?

A.

The synaptic cleft is the space between a single neuron's dendrites and axon terminals in which intracellular communication occurs through the release of neurotransmitters allowing for signal conduction throughout the central nervous system.

B.

The synaptic cleft is the space between the cell body and axon terminals that allows for release of neurotransmitters from the presynaptic neuron for intercellular communication with an adjacent neuron (post synaptic neuron).

C.

The synaptic cleft is an area where dendrites and axon terminals are within close proximity, allowing for the release of a neurotransmitter from a presynaptic neuron that can interact with receptors on dendritic cells of a post synaptic neuron, which is the main basis for intercellular communication of neurons.

3.75 points  

QUESTION 17

1.       When dopamine (subtype 2) receptors are blocked in this pathway (system), it is evident by EPS.

A.

Mesocortical

B.

Tuberoinfundibular

C.

Nigrostriatal

D.

Mesolimbic

3.75 points  

QUESTION 18

1.       Upon blocking a Serotonin reuptake pump, what happens in the synaptic cleft and on the post synaptic cell membrane?

A.

The result will be an increase in available Serotonin in the synaptic cleft causing the post synaptic cell to increase the number of Serotonin receptors.

B.

The result will be an increase in the available Serotonin in the synaptic cleft causing the post synaptic neuron to reduce the number of Serotonin receptors.

C.

The result will be an increase in Serotonin in the synaptic cleft resulting in an increase in reuptake pumps on the presynaptic neuron.

D.

The result will be an increase in Serotonin in the synaptic cleft resulting in a decrease in reuptake pumps on the pre-synaptic neuron.

3.75 points  

QUESTION 19

1.       Serotonin (5HT) is a neurotransmitter associated with mood, sleep, and psychosis. There are several serotonin receptors all over the human body. A unique aspect of the second generation antipsychotics is their ability to block 5HT2a receptors. What is the effect of this inhibition?

A.

Stabilizes dopamine concentrations in the CNS

B.

Induces anxiety

C.

Causes hallucinations

D.

Reduces platelet function

3.75 points  

QUESTION 20

1.       A patient arrives in the ED via EMS having a grand mal seizure. The ED physician instructs the RN to give 10 milligrams of Diazepam IV X1 dose STAT. The patient's seizure breaks within 2 minutes of the Diazepam being administered. The mechanism by which this medication causes rapid resolution of seizure activity is via which receptor type (effector pathway/receptor subtype)?

A.

Slow effector pathways/G-protein coupled receptor

B.

Slow effector pathway/ion channel

C.

Rapid effector pathways/G-protein coupled receptor

D.

Rapid effector pathway/ion channel